
In ‘major milestone,’ FDA approves first cell therapy for solid tumors
After 40 years in development, the first TIL therapy received accelerated approval from the FDA for advanced melanoma. The therapy, called Amtagvi or lifileucel, is the first cell therapy approved for a solid tumor. During a phase 2 clinical trial, 31% of patients responded to the therapy, with 42% of those patients continuing to respond…